P. Enzinger

发表

NCCN Clinical Practice Guidelines in Oncology: colon cancer.

M. Choti, J. Fleshman, C. Willett, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines.

M. Choti, C. Willett, Yi-Jen Chen, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

Ahmed Kamel, Howard S Hochster, Christopher G Willett, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis.

M. Meyerson, T. Godfrey, R. Beroukhim, 2012, Cancer research.

Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Quan P. Ly, Michael Gibson, Rajesh N Keswani, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

O-Methylguanine DNA Methyltransferase Deficiency and Response toTemozolomide-BasedTherapy in Patients with Neuroendocrine Tumors

Jeffrey W. Clark, J. Meyerhardt, C. Fuchs, 2008 .

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

Marek Ancukiewicz, Vivek Sindhwani, Onofrio A Catalano, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.

Alona Muzikansky, Colleen Lawrence, Jeffrey W. Clark, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal (GEJ) junction or gastric (G) cancer.

E. Schmidt, P. Philip, J. Wigginton, 2017 .

Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.

John V Heymach, Thomas J Lynch, J. Meyerhardt, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rectal Cancer

M. Choti, A. Benson, C. Willett, 2018, Springer International Publishing.

A stakeholder-driven approach to improve the informed consent process for palliative chemotherapy.

P. Enzinger, D. Schrag, N. Meropol, 2017, Patient education and counseling.

Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer

J. Meyerhardt, R. Bueno, N. Choi, 2016, BMC Cancer.

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma.

J. Meyerhardt, P. Fidias, J. Temel, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy.

W. Willett, E. Winer, J. Meyerhardt, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer

Jeffrey W. Clark, C. Earle, J. Meyerhardt, 2007, Cancer Chemotherapy and Pharmacology.

Physical activity in older adults with metastatic gastrointestinal cancer: a pilot and feasibility study

J. Meyerhardt, P. Enzinger, B. Wolpin, 2022, BMJ Open Sport & Exercise Medicine.

Phase I study of geWtinib, irinotecan, 5-Xuorouracil and leucovorin in patients with metastatic colorectal cancer

C. Earle, J. Dancey, S. Ogino, 2007 .

Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer.

Jeffrey W. Clark, C. Earle, J. Meyerhardt, 2006, Clinical colorectal cancer.

A Phase II Study of Modified deGramont 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Treated Patients with Metastatic Colorectal Cancer

Jeffrey W. Clark, C. Earle, C. Fuchs, 2003, Cancer investigation.

Oncogenesis and Colon Exhibit Distinct Patterns of Genome Instability and Gastrointestinal Adenocarcinomas of the Esophagus, Stomach,

M. Meyerson, T. Godfrey, R. Beroukhim, 2012 .

A Phase II Trial of Irinotecan and Cisplatin in Patients with Metastatic Neuroendocrine Tumors

Jeffrey W. Clark, C. Earle, Bingyan Wu, 2006, Digestive Diseases and Sciences.

Irinotecan in esophageal cancer.

P. Enzinger, D. Ilson, 2000, Oncology.

Adjuvant therapy for gastric cancer: revisiting the past to clarify the future.

C. Fuchs, P. Enzinger, G. Brooks, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.

Jeffrey W. Clark, C. Fuchs, P. Enzinger, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.

C. Earle, J. Meyerhardt, P. Fidias, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma

M. Shah, P. Enzinger, Xiaolong Fu, 2021, Future oncology.

Irinotecan and cisplatin in upper gastrointestinal malignancies.

L. Saltz, P. Enzinger, D. Kelsen, 1998, Oncology.

Colon cancer, version 3.2014.

James D. Murphy, C. Willett, Yi-Jen Chen, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.

Jeffrey W. Clark, C. Earle, J. Meyerhardt, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer.

D. Rattner, J. Meyerhardt, R. Bueno, 2013, The oncologist.

Gastric Cancer, Version 2.2022

Quan P. Ly, J. Ajani, J. Lacy, 2022 .

Efﬁcacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

Jeffrey W. Clark, D. Sahani, J. Meyerhardt, 2009 .

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors

Jeffrey W. Clark, M. Fishman, T. Lynch, 2006, Cancer.

Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).

Yoon-Koo Kang, P. Enzinger, Z. Wainberg, 2021 .

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Sung-Bae Kim, M. Shah, P. Sunpaweravong, 2021, The Lancet.

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.

Y. Bang, C. Fuchs, E. Van Cutsem, 2020, JAMA oncology.

Chemotherapy in esophageal cancer.

P. Enzinger, D. Kelsen, D. Ilson, 1999, Seminars in oncology.

Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines.

M. Choti, J. Fleshman, C. Willett, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer

L. Sequist, C. Fuchs, A. Hezel, 2008 .

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.

Sung-Bae Kim, M. Shah, F. Lordick, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101.

C. Willett, C. Fuchs, J. Tepper, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOLFOX plus ziv‐aflibercept or placebo in first‐line metastatic esophagogastric adenocarcinoma: A double‐blind, randomized, multicenter phase 2 trial

Jeffrey W. Clark, C. Azzoli, J. Meyerhardt, 2019, Cancer.

Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Quan P. Ly, J. Ajani, J. Lacy, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer.

C. Earle, J. Meyerhardt, C. Fuchs, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Anal carcinoma: Clinical practice guidelines in oncology™

M. Choti, J. Fleshman, J. Berlin, 2010 .

CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer.

A. Benson, R. Goldberg, P. Enzinger, 2010 .

Patterns of chemotherapy (CT) use in a U.S.-wide cohort of patients (pts) with metastatic gastric cancer (MGC).

J. Meyerhardt, C. Fuchs, P. Enzinger, 2018 .

Osteonecrosis of the jaw associated with ziv-aflibercept.

P. Enzinger, A. Villa, N. Treister, 2016, Journal of gastrointestinal oncology.

LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study

M. Shah, P. Sunpaweravong, P. Enzinger, 2020 .

The 3-Hole Minimally Invasive Esophagectomy: A Safe Procedure Following Neoadjuvant Chemotherapy and Radiation.

R. Bueno, B. Yeap, P. Enzinger, 2015, Seminars in thoracic and cardiovascular surgery.

Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma.

J. Meyerhardt, P. Enzinger, D. Schrag, 2014, The oncologist.

Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer’s Perspective

P. Enzinger, Shaohua Zhang, Y. Zhong, 2022, PharmacoEconomics.

Outcomes of trimodality CROSS regimen in older adults with locally advanced esophageal cancer.

P. Enzinger, H. Mamon, M. Jaklitsch, 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Prevalence and significance of subcentimeter hepatic lesions in patients with localized pancreatic adenocarcinoma.

A. Shinagare, P. Enzinger, T. Hong, 2012, Practical radiation oncology.

Phase II cisplatin, irinotecan, cetuximab and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer.

N. Choi, C. Fuchs, P. Enzinger, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III KEYNOTE-590 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer.

M. Shah, P. Enzinger, Y. Zhu, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Sung-Bae Kim, M. Shah, P. Sunpaweravong, 2021 .

Phase II study of cetuximab in patients with unresectable or metastatic hepatocellular carcinoma.

A. Zhu, P. Enzinger, D. Ryan, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of temsirolimus in combination with gemcitabine in previously untreated metastatic pancreatic cancer.

A. Hezel, P. Enzinger, D. Ryan, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial

P. Philip, M. Shah, Y. Bang, 2018, JAMA oncology.

Esophageal cancer.

P. Enzinger, R. Mayer, Robert J Mayer, 2003, The New England journal of medicine.

Clinical Practice Guidelines in Oncology TM

M. Choti, J. Fleshman, C. Willett, 2009 .

Localized Colon Cancer, version 3.2013

M. Choti, C. Willett, C. Fuchs, 2013 .

Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines.

M. Choti, C. Willett, Yi-Jen Chen, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C

Huyuan Yang, P. Enzinger, J. Bendell, 2017, Investigational New Drugs.

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.

J. Lacy, S. Park, Y. Bang, 2020, The Lancet. Oncology.

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.

M. Shah, P. Enzinger, B. Cho, 2019, Future oncology.

Gastrointestinal cancer in older patients.

P. Enzinger, R. Mayer, 2004, Seminars in oncology.

Colon Cancer and Other Gastrointestinal Malignancies

P. Enzinger, R. Mayer, 2003 .

Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial

Jeffrey W. Clark, N. Hacohen, J. Meyerhardt, 2023, Nature Medicine.

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study

Sung-Bae Kim, J. Lunceford, M. Shah, 2019, JAMA oncology.

CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma

Jeffrey W. Clark, M. Loda, J. Meyerhardt, 2007, Virchows Archiv.

Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer

Shuji Ogino, Jeffrey W. Clark, Massimo Loda, 2005, Clinical Cancer Research.

SO-26 Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients

Jeffrey W. Clark, N. Hacohen, J. Meyerhardt, 2020 .

Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer

J. Meyerhardt, R. Jain, A. Zhu, 2012, PloS one.

NCCN Clinical Practice Guidelines in Oncology: rectal cancer.

Christopher Willett, Michael A Choti, Krystyna Kiel, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.

Jeffrey W. Clark, C. Earle, J. Meyerhardt, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors.

Jeffrey W. Clark, C. Earle, J. Meyerhardt, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II trial of gemcitabine for metastatic neuroendocrine tumors

Jeffrey W. Clark, T. Lynch, P. Enzinger, 2004, Cancer.

Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.

Jeffrey W. Clark, D. Sahani, J. Meyerhardt, 2010, The Lancet. Oncology.

Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival

Jeffrey W. Clark, A. Bass, C. Fuchs, 2021, Journal for ImmunoTherapy of Cancer.

NCCN clinical practice guidelines in oncology. Anal carcinoma.

M. Choti, J. Fleshman, J. Berlin, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.

Sung-Bae Kim, M. Shah, P. Enzinger, 2019, Journal of Clinical Oncology.

Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer

Rachel B. Keller, E. Cerami, J. Meyerhardt, 2023, JCO precision oncology.

Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies

C. Tournigand, J. Ajani, M. Shah, 2022, Cancers.

Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome

O. Elemento, M. Pittman, P. Philip, 2020, Clinical Cancer Research.

Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.

Yoon-Koo Kang, P. Enzinger, E. Hitre, 2022, The Lancet. Oncology.

Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma

Y. Bang, P. Enzinger, Z. Wainberg, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.

J. Lacy, M. Shah, C. Fuchs, 2019, The Lancet. Oncology.

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.

Jeffrey W. Clark, J. Meyerhardt, C. Fuchs, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).

J. Meyerhardt, C. Willett, C. Fuchs, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.

R. Goldberg, M. Tempero, P. Enzinger, 2009, Journal of Clinical Oncology.

Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance)

K. Owzar, M. Ratain, C. Willet, 2021, Pharmacogenetics and genomics.

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.

Alona Muzikansky, Keith Stuart, Jeffrey W. Clark, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC).

J. Lacy, S. Park, Y. Bang, 2019, Journal of Clinical Oncology.

195TiP GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)

J. Ajani, Y. Bang, Ruifeng Xu, 2020 .

198TiP SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)

J. Ajani, Y. Bang, Ruifeng Xu, 2020 .

A Phase II Trial of Irinotecan in Patients with Previously Untreated Advanced Esophageal and Gastric Adenocarcinoma

Jeffrey W. Clark, C. Earle, C. Fuchs, 2005, Digestive Diseases and Sciences.

Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.

G. Schwartz, L. Saltz, P. Enzinger, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I I T rial o f W eekly I rinotecan P lus C isplatin in A dvanced E sophageal C ancer

Ying Huang, L. Saltz, P. Enzinger, 1999 .

A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer

Jeffrey W. Clark, W. Goessling, R. Heist, 2020, Investigational New Drugs.

A Phase II Trial of Vinorelbine in Patients with Advanced Gastroesophageal Adenocarcinoma

Jeffrey W. Clark, P. Fidias, C. Fuchs, 2006, Cancer investigation.

Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.

Jeffrey W. Clark, C. Earle, J. Meyerhardt, 2006, Clinical colorectal cancer.

Multicenter phase 2: Capecitabine (CAP) + oxaliplatin (OX) + bevacizumab (BEV) + trastuzumab (TRAS) for patients (pts) with metastatic esophagogastric cancer (MEGCA).

J. Meyerhardt, C. Fuchs, P. Enzinger, 2015 .

FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC).

Yoon-Koo Kang, P. Enzinger, E. Hitre, 2021 .

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

Jeffrey W. Clark, J. Meyerhardt, A. Zhu, 2007, Cancer.

CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.

A. Benson, R. Goldberg, P. Enzinger, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multidisciplinary Approach in Improving Survival Outcome of Early-Stage Gastric Cancer.

P. Enzinger, Jiping Wang, Xuefei Wang, 2020, The Journal of surgical research.

Identification of potentially avoidable hospitalizations in patients with GI cancer.

H. Uno, J. Meyerhardt, C. Fuchs, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Colon Cancer , Version 3 . 2014 Clinical Practice Guidelines in Oncology

A. Benson, James D. Murphy, C. Willett, 2014 .

Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer

Jeffrey W. Clark, C. Earle, J. Meyerhardt, 2006, Cancer Chemotherapy and Pharmacology.

Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

Quan P. Ly, J. Ajani, J. Lacy, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

A Phase II Study of Ziv-Aflibercept in Patients With Advanced Extrapancreatic Neuroendocrine Tumors

Jeffrey W. Clark, P. Enzinger, N. Horick, 2022, Pancreas.

Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma

J. Mancias, A. Bullock, P. Enzinger, 2015, Journal of Cancer.

Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).

J. Lacy, S. Park, Y. Bang, 2018 .

Phase II clinical trial of 13‐cis‐retinoic acid and interferon‐α‐2a in patients with advanced esophageal carcinoma

L. Saltz, P. Enzinger, D. Kelsen, 1999, Cancer.

A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer

Jeffrey W. Clark, A. Hezel, P. Enzinger, 2012, Investigational New Drugs.

A phase II clinical trial of ganetespib (STA-9090) in previously treated patients with advanced esophagogastric cancers.

W. Goessling, R. Heist, P. Enzinger, 2013 .

Rectal cancer, version 2.2015: Featured updates to the NCCN guidelines

James D. Murphy, C. Willett, C. Fuchs, 2015 .

Feasibility of computer-based self-administered cancer-specific geriatric assessment in older patients with gastrointestinal malignancy.

J. Meyerhardt, C. Fuchs, P. Enzinger, 2013, The oncologist.

The Combination of Capecitabine and Thalidomide in Previously Treated, Refractory Metastatic Colorectal Cancer

Jeffrey W. Clark, C. Earle, Bingyan Wu, 2006, American journal of clinical oncology.

Contribution of FDG-PET/CT to the management of esophageal cancer patients at multidisciplinary tumor board conferences

H. Hatabu, P. Enzinger, H. Mamon, 2020, European journal of radiology open.

Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study

J. Ajani, Y. Bang, E. Van Cutsem, 2023, Journal of Clinical Oncology.

Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2− locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW.

J. Ajani, P. Sunpaweravong, Y. Bang, 2023, Journal of Clinical Oncology.

Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)—ILUSTRO Cohort 3.

J. Ajani, M. Shah, Y. Bang, 2021 .

Rectal Cancer, Version 2.2015.

James D. Murphy, C. Willett, Yi-Jen Chen, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Impact of Hospital Volume on Recurrence and Survival After Surgery for Gastric Cancer

J. Meyerhardt, C. Fuchs, P. Enzinger, 2007, Annals of surgery.

Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer.

W. Goessling, J. Meyerhardt, C. Fuchs, 2013, The oncologist.

Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept/placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA).

C. Azzoli, J. Meyerhardt, C. Fuchs, 2016 .

Alkaline fuel cells applications

Viktor Hacker, Michael Muhr, Josef Gsellmann, 2000 .

Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response

P. Enzinger, J. Hornick, H. Mamon, 2018, Annals of Nuclear Medicine.

Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer

C. Earle, J. Meyerhardt, C. Fuchs, 2007 .

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.

Sung-Bae Kim, M. Shah, P. Enzinger, 2019, Journal of Clinical Oncology.

Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer

J. Meyerhardt, R. Bueno, N. Choi, 2016, BMC Cancer.

Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma?

P. Enzinger, T. Hong, I. Chau, 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

A Phase II Study of Doxorubicin, Cisplatin, and 5-Fluorouracil in Patients with Advanced Adenocarcinoma of the Stomach or Esophagus

Jeffrey W. Clark, Bingyan Wu, T. Lynch, 2006, Cancer investigation.

A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.

P. Catalano, R. Bueno, P. Enzinger, 2017, Diseases of the esophagus.

G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans

P. Enzinger, B. Wolpin, D. Rubinson, 2023, Journal for ImmunoTherapy of Cancer.

A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer

C. Earle, J. Meyerhardt, C. Fuchs, 2007 .

Florid Foreign Body-type Giant Cell Response to Keratin Is Associated With Improved Overall Survival in Patients Receiving Preoperative Therapy for Esophageal Squamous Cell Carcinoma

A. Bass, P. Enzinger, V. Deshpande, 2021, The American journal of surgical pathology.

Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+ gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).

S. Park, Y. Bang, Yoon-Koo Kang, 2018 .

Rectal cancer clinical practice guidelines in oncology.

M. Choti, T. Yeatman, C. Willett, 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

Greenhouse Gas Benefits of a Biogas Plant in Austria

Naomi Pena, Gerfried Jungmeier, Reinhard Padinger, 2010 .

First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study.

Sung-Bae Kim, M. Shah, P. Sunpaweravong, 2022, Journal of Clinical Oncology.

Multicenter phase Ib/II study of everolimus (RAD001) and tivozanib (AV-951) in patients with refractory, metastatic colorectal cancer.

W. Goessling, J. Meyerhardt, C. Fuchs, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.

Jeffrey W. Clark, C. Earle, J. Meyerhardt, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Quan P. Ly, Rajesh N Keswani, Kory Jasperson, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

J. Ajani, C. Willett, D. Bentrem, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Clinical Practice Guidelines in Oncology: rectal cancer.

R. Dilawari, D. Early, P. Enzinger, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Rectal cancer.

M. Choti, Yi-Jen Chen, C. Fuchs, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Prediction of response to temozolomide (TMZ)-based therapy by loss of MGMT expression in patients with advanced neuroendocrine tumors (NET)

Jeffrey W. Clark, J. Meyerhardt, C. Fuchs, 2007 .

134MO Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocar

P. Enzinger, D. Ilson, J. Huang, 2023, Annals of Oncology.